Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study. 2021

Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
Department of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milano, Italy.

Despite the introduction of effective combination antiretroviral therapy (cART) AIDS-related Kaposi Sarcoma (AIDS-KS) remains the most common malignancy in HIV positive patients. In advanced stage or progressive forms, chemotherapy (CT) in combination with cART is the treatment of choice. The aim of the study is to evaluate efficacy and tolerability of Pegylated Liposomal Doxorubicin (PLD) as first line CT in AIDS-KS. In this single institution retrospective study PLD (20 mg/m2 IV every 2 weeks for 6 or 12 cycles) in combination with cART was administered in poor risk and some cases of good prognosis or limited cutaneous disease. Response rate and adverse events to treatment was evaluated. We enrolled 33 patients with AIDS-KS: median age 44ys, male 90.9%, Caucasian 72.7%, cART-naïve (simultaneous diagnosis of HIV infection and KS) 84.4%, median lymphocyte CD4+ count 134cells, median HIV viral load 4.9 log10 copies/ml. 32 patients were assigned to a Poor Risk KS stage. Grade 3-4 toxicity was reported in 9 patients. No cardiovascular events or severe sepsis were described. Complete response was reported in 25 of 31 patients evaluable for efficacy. After a median follow-up of 52 months the 3-years PFS was 68.6%. PLD associated with cART is an effective, feasible and well tolerated first-line CT in advanced AIDS-KS.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's

Related Publications

Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
January 2007, International journal of nanomedicine,
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
January 2001, Acta dermato-venereologica,
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
August 1993, Lancet (London, England),
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
January 1993, Clinical oncology (Royal College of Radiologists (Great Britain)),
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
January 2007, The oncologist,
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
February 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
March 1997, Clinical pharmacology and therapeutics,
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
June 2008, The Journal of investigative dermatology,
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
June 1994, The Clinical investigator,
Davide Dalu, and Cinzia Fasola, and Luca Ammoni, and Davide De Francesco, and Maria Silvia Cona, and Selene Rota, and Sabrina Ferrario, and Anna Gambaro, and Nicoletta Tosca, and Sheila Piva, and Nicla La Verde
February 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!